Canadian journal of microbiology · 2025
High prevalence of Candida species in the respiratory tract of patients diagnosed with SARS-CoV-2.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Spadari Cristina de Castro, Esposito Fernanda Ribeiro Dos Santos, Sano Elder, Aires Caroline Cotrim, Conselheiro Juliana Amorim, Barone Gisely Toledo, Reis-Menezes Adriana Araújo, de Oliveira Danielle Bruna Leal, Luiz Durigon Edison, Sampaio Jorge M, Lincopan Nilton, Ishida Kelly
Аннотация
Coinfection and secondary infection by fungi in patients with viral pulmonary infection, especially SARS-CoV-2, are important factors that worsen the prognosis and are associated to increased death rates. This work aims to report the prevalence of Candida isolates in bronchoalveolar and nasopharyngeal samples from suspected COVID-19 patients in the first-second pandemic waves and their antifungal resistance profile. From 2321 patients, 29.04% were diagnosed with SARS-CoV-2 infection. The yeast isolation rate of 6.97% (47/674) from positive SARS-CoV-2 was statistically higher than 4.43% (73/1647) from negative SARS-CoV-2 patients (p = 0.0177). Among yeasts, the most prevalent species was Candida albicans (63/120), with four being azole-resistant isolates (6.35%); however, other emerging and less susceptible species were also isolated, such as Candida guilliermondii (11), Candida glabrata (5), Candida lusitaniae (4), Candida krusei (1), and Candida norvegensis (1). Here, we highlighted Candida prevalence in respiratory tract, emphasizing the relevance for surveillance in SARS-CoV-2/COVID patients for improvement of management as well as patient outcomes.